title: Enhanced free radical scavenging and decreased lipid peroxidation in the rat fetal brain after treatment with ethyl docosahexaenoate.
abstract: In order to explore possible mechanisms to explain previously observed decreases in fetal brain lipid peroxidation (LPO) following intraamniotic administration of ethyl docosahexaenoate (Et-DHA) to near term fetuses, the hydroxyl radical trapping capacity of Et-DHA treated fetal brain preparations was compared to control ethyl oleate injected fetuses by electron spin resonance using 5,5'-dimethyl-1-pyrroline N-oxide (DMPO) probe. Lipid extracts from control brains showed little hydroxyl radical scavenging activity, whereas those from the Et-DHA injected animals exhibited an almost 70% decrease in the amount of DMPO-OH adducts. A marked decrease (58%) in LPO formation was noticed in the Et-DHA treated animals compared to controls. The Et-DHA treatment related trapping capacity resided in the phospholipid fraction of the lipid extract, which was enriched in both docosahexaenoic acid and aminophospholipid contents. The decreased LPO production, as well as increased production of prostaglandin E(2) and nitric oxide by the fetal brain following Et-DHA administration, could be mimicked by a synthetic quinone possessing both hydroxyl radical producing and LPO propagation inhibiting properties. The data are consistent with the possibility that the neuroprotective effect of Et-DHA might be due to possible free radical scavenging ability of the brain tissue and interference with LPO propagation.
authors.affiliation: Department of Neurobiology, Weizmann Institute of Science, Rehovet, Israel.
authors.forename: P
authors.initials: P
authors.lastname: Green
authors.forename: S
authors.initials: S
authors.lastname: Glozman
authors.forename: L
authors.initials: L
authors.lastname: Weiner
authors.forename: E
authors.initials: E
authors.lastname: Yavin
mesh_terms: D000650:Amnion; D000818:Animals; D000975:Antioxidants / Q000032:analysis; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D001923:Brain Chemistry; D003497:Cyclic N-Oxides; D015232:Dinoprostone / Q000032:analysis / Q000378:metabolism; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D004578:Electron Spin Resonance Spectroscopy; D005260:Female; D005333:Fetus; D016166:Free Radical Scavengers / Q000378:metabolism*; D015227:Lipid Peroxidation / Q000187:drug effects*; D008054:Lipid Peroxides / Q000378:metabolism; D008055:Lipids / Q000032:analysis; D009569:Nitric Oxide / Q000032:analysis / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism; D011247:Pregnancy; D051381:Rats; D017208:Rats, Wistar; D013113:Spin Labels; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
chemical_list: D000975:Antioxidants; D003497:Cyclic N-Oxides; D016166:Free Radical Scavengers; D008054:Lipid Peroxides; D008055:Lipids; D010743:Phospholipids; D013113:Spin Labels; D017392:Thiobarbituric Acid Reactive Substances; D004281:Docosahexaenoic Acids; D009569:Nitric Oxide; C017245:5,5-dimethyl-1-pyrroline-1-oxide; D015232:Dinoprostone